Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate.

Eur Arch Psychiatry Clin Neurosci

Fondation FondaMental Fondation de Coopération Scientifique en Santé Mentale, Eq Psychiatrie Génétique, INSERM U955, DHU Pepsy, Pôle de Psychiatrie du Groupe des Hôpitaux Universitaires de Mondor, Université Paris Est-Créteil, 94000, Créteil, France,

Published: March 2014

Recent studies have shown a strong link between Toxoplasma gondii infection and psychiatric disorders, especially schizophrenia and bipolar disorders (odd ratio ≈2.7 for each disorder). Antipsychotic drugs and mood stabilizers may have anti-toxoplasmic activity that potentially may be associated with better effectiveness in these disorders, but previous results have been few in number and conflicting. We therefore sought to determine which daily prescribed antipsychotics and mood stabilizer have the best anti-toxoplasmic activity during the development phase of the parasite. In the present study, we examined the effects of commonly used antipsychotic drugs (amisulpride, cyamemazine, fluphenazine, haloperidol, levomepromazine, loxapine, olanzapine, risperidone and tiapride) and one mood-stabilizing agent (valproate) on toxoplasmic activity. We replicated that fluphenazine has a high anti-toxoplasmic activity, but it does not seem to be a phenothiazine-specific class effect: indeed, we found that another first-generation antipsychotic, zuclopenthixol, has a high anti-toxoplasmic activity. Valproate, tiapride and amisulpride have no anti-toxoplasmic activity on parasite growth, and the other antipsychotic drugs showed low or intermediate anti-toxoplasmic activity. As it is not possible to know the intracellular concentrations of antipsychotics in the brain, further clinical studies are warranted to determine whether these in vitro findings have potential implications in treatment of toxo-positive patients with schizophrenia. These findings may be potentially relevant for the choice of the first-line antipsychotic drug or mood stabilizer in previously infected patients.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00406-013-0413-4DOI Listing

Publication Analysis

Top Keywords

anti-toxoplasmic activity
28
antipsychotic drugs
16
activity
8
mood stabilizer
8
high anti-toxoplasmic
8
anti-toxoplasmic
7
antipsychotic
6
comparative analysis
4
analysis anti-toxoplasmic
4
activity antipsychotic
4

Similar Publications

Purpose: Toxoplasmosis is caused by the parasite Toxoplasma gondii (T. gondii). In immunocompetent individuals, the infection is often asymptomatic; however, in expectant mothers and those with immune system deficiencies, complications may arise.

View Article and Find Full Text PDF
Article Synopsis
  • * The study examined four eyes from three immunocompromised patients, highlighting that, despite negative tests for anti-toxoplasma immunoglobulin M, all tested positive for immunoglobulin G and exhibited severe symptoms like vitritis and distinct chorioretinitis lesions.
  • * All patients received effective treatment combining systemic and intravitreal anti-toxoplasmic drugs, emphasizing the need for clinicians to consider TC in immunosuppressed individuals experiencing new uveitis episodes to prevent misdiagnosis.
View Article and Find Full Text PDF

Background: Current chemical treatments for toxoplasmosis have side effects, researchers are looking for herbal remedies with minimal side effects and the best effectiveness. This study aimed to evaluate the anti-toxoplasmic effects of silver nanoparticles based on Sambucus ebulus (Ag-NPs-S. ebulus) and Feijoa sellowiana (Ag-NPs-F.

View Article and Find Full Text PDF

Blockage of Galectin-Receptor Interactions Attenuates Mouse Hepatic Pathology Induced by Infection.

Front Immunol

August 2022

Department of Parasitology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.

(), one of the most important Apicomplexan protozoa, causes toxoplasmosis in human throughout the world. Galectin (Gal)-9 triggers a series of immune events binding to its receptors, including T cell immunoglobulin and mucin-containing molecule 3, CD137, CD44, and protein disulfide isomerase. To examine the regulatory role of galectin-receptor interactions in anti-toxoplasmic activities, C57BL/6 mice were infected with RH strain and intraperitoneally injected with alpha (α)-lactose to block the interactions of galectins and their receptors.

View Article and Find Full Text PDF

Anti-toxoplasma and Cytotoxic Activities of Holothuria leucospilota Extract and TiONPs In vitro and In vivo.

Infect Disord Drug Targets

June 2022

Cellular and Molecular Research Center, Cellular and Molecular Medicine Institute & Department of Medical Parasitology and Mycology, Urmia University of Medical Sciences, Urmia, Iran.

Background: An impressive treatment for toxoplasmosis is the combinatory use of sulfadiazine and pyrimethamine. However, both the drugs involve significant side effects and toxicity for the host. Therefore, the discovery of new anti-toxoplasma medications with high efficacy and less to no side effects is urgently needed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!